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Frontopolar cortexPharmacological studies point to a role of the neurotransmitter serotonin (5-HT) in regulating the preference
for risky decisions, yet the functional contribution of speciﬁc 5-HT receptors remains to be clariﬁed. We used
pharmacological fMRI to investigate the role of the 5-HT2A receptors in processing negative outcomes and
regulating risk-averse behavior. During fMRI, twenty healthy volunteers performed a gambling task under
two conditions: with or without blocking the 5-HT2A receptors. The volunteers repeatedly chose between
small, likely rewards and large, unlikely rewards. Choices were balanced in terms of expected utility and po-
tential loss. Acute blockade of the 5-HT2A receptors with ketanserin made participants more risk-averse.
Ketanserin selectively reduced the neural response of the frontopolar cortex to negative outcomes that
were caused by low-risk choices and were associated with large missed rewards. In the context of normal
5-HT2A receptor function, ventral striatum displayed a stronger response to low-risk negative outcomes in
risk-taking as opposed to risk-averse individuals. This (negative) correlation between the striatal response
to low-risk negative outcomes and risk-averse choice behavior was abolished by 5-HT2A receptor blockade.
The results provide the ﬁrst evidence for a critical role of 5-HT2A receptor function in regulating risk-averse
behavior. We suggest that the 5-HT2A receptor system facilitates risk-taking behavior by modulating the out-
come evaluation of “missed” reward. These results have implications for understanding the neural basis of
abnormal risk-taking behavior, for instance in pathological gamblers.
© 2013 Elsevier Inc. Open access under CC BY license.Introduction
When choosing between risky alternatives, people take into
account both probabilities and valuation (utility) of possible outcomes,
considering probability-weighted expectation over possible utilities
(Von Neumann et al., 2007). For risky ﬁnancial decisions, people's
choice behavior shows systematic deviations from the standard
economic view of expected utility maximization (Rieskamp, 2008).
For instance, when playing lotteries, excessive “decision weights” are
assigned to low-probability outcomes (Hsu et al., 2009). Such non-
linear attributes that bias objective probabilities have been imple-
mented in models of behavioral economics such as the prospect theory
(Kahneman and Tversky, 1979), yet it is only recently that researchers
have started to explore its neural underpinnings (e.g. Christopoulos etagnetic Resonance, Copenhagen
DK 2650, Denmark.
 license.al., 2009; Huettel et al., 2006). Unveiling the neural mechanisms that
bias the “decision weights” of risk-taking behavior is critical to the un-
derstanding of pathological states of impaired ﬁnancial decision-
making such as gambling addiction.
The availability of striatal dopamine D1 receptors has recently
been shown to be negatively correlated with the degree of
nonlinearity of the risk weighting function (Takahashi et al., 2010).
A reduced striatal D1 receptor density was associated with a more
pronounced overestimation of low winning probabilities and under-
estimation of high winning probabilities. Genetic differences in
striatal dopamine availability have also been proposed to explain
differences in individuals risk taking behavior (Mata et al., 2012).
The neurotransmitter serotonin (5-HT) may also play a critical
role in biasing the “decision weights” guiding risky behaviors. 5-HT
has been implicated in processing and learning from aversive stimuli
(Tanaka et al., 2009) as well as in the prediction of future punishment
(Boureau and Dayan, 2011; Crockett et al., 2012). Acute reduction of
central serotonin levels with acute dietary tryptophan depletion
(ATD) increases the propensity to make risky choices in a gambling
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primates (Long et al., 2009). In healthy individuals, tryptophan sup-
plements altered the weighting of gains and small losses and reduced
the reﬂection effect (being risk-averse for gains and risk-seeking for
losses) (Murphy et al., 2009). Despite the clear involvement of 5-HT
in regulating risk-taking behavior the functional contribution of
speciﬁc 5-HT receptors remains to be clariﬁed.
The 5-HT2A receptors have excitatory effects on the postsynaptic
neurons and are abundantly and uniformly distributed, primarily in
cortical, but also in subcortical regions (Van Dyck et al., 2000). Inter-
estingly, 5-HT2A receptor stimulation increases activity in the
nigrostriatal dopamine pathway modulating phasic, but not tonic, do-
pamine efﬂux (Alex and Pehek, 2007). Impulsive behavior, a domi-
nant feature in pathological gamblers, has been attributed to a
polymorphism (1438A/G) in the promoter of the 5-HT2A receptor
gene (Nomura et al., 2006) and recent imaging studies have linked
frontolimbic 5-HT2A binding to neuroticism (Frokjaer et al., 2008).
Prefrontal 2A receptors have also been implicated in regulating the
amygdala–prefrontal coupling during aversive face processing
(Fisher et al., 2009). In order to explore the role of 5-HT2A receptor-
mediated neurotransmission in regulating risk behavior we used
functional magnetic resonance imaging (fMRI) in healthy volunteers
during the performance of a gambling task while blocking 5-HT2A
receptor function with ketanserin.
Compared to a state with normal 5-HT2A receptor function, we
expected ketanserin to alter the response in several regions that are
modulated by serotonergic projections and that play key roles in re-
ward processing (Liu et al., 2011). For instance, the lateral frontopolar
cortex (lFPC) has been linked to choices between options associated
with different risks and reward magnitudes (Rogers et al., 1999b)
and to tracking missed reward (Boorman et al., 2009, 2011).
Goal-directed behavior and decision-making are known to rely on
frontopolar–striatal projections (Haber, 2011). During primary
rewarding stimuli, these fronto–striatal interactions are sensitive to
serotonergic drugs (Abler et al., 2012). Global serotonergic challenges
have recently been found to modulate the activity of dorsomedial
prefrontal cortex and amygdala when subjects missed a large mone-
tary reward (Macoveanu et al., in press). Increased 5-HT availability
by selective serotonin uptake inhibitors (SSRIs) has been reported
to reduce the neural response of ventral striatum (VS) to primary
rewarding stimuli (Abler et al., 2012; McCabe et al., 2010). Given
the relevance of 5-HT for processing and predicting aversive stimuli
(Boureau and Dayan, 2011; Cools et al., 2010; Crockett et al., 2012),
we predicted that blocking the excitatory action of the 5-HT2A recep-
tors would modulate the neural response in reward-related regions
while subjects evaluate monetary outcomes, thereby altering risk-
taking behavior.
Patients and methods
Participants
Twenty right-handed healthy adults (7 females) age ± SD of
32.1 ± 5.9 years were included in the fMRI study. None reported a
history of stimulant abuse, neurological or psychiatric disorders. All
subjects were naïve for antipsychotics and antidepressants according
to self-report. Written informed consent was obtained prior to the
MRI scanning sessions. The study was approved by the Copenhagen
Ethics Committee (KF 01-2006-20).
Card gambling task
During fMRI, participants performed a gambling task previously
described in detail in Macoveanu et al. (in press). Each trial started
with an information screen displaying the total amount of money
available in Danish Kroner (1$ ≈ 6 DKK) and the bet size. Sevenplaying cards were randomly distributed into two sets displayed
face down (Fig. 1A). One of the cards was the “ace of hearts” and sub-
jects were asked to choose one of the two sets that they believed
contained the ace. Upon selection, the location of the ace was
revealed. A correct choice was rewarded with the amount displayed
bellow the set. For a wrong choice the subject would lose the bet.
Fig. 1B shows the six possible risk choices with associated potential
rewards. The experimental design enabled us to assess differential re-
sponses to outcomes depending on whether the decision preceding it
was risk-averse or risk-taking. The paradigm equated the expected
values of the high and low risk choices (i.e., the sum of probabilistical-
ly weighted wins and losses) and was tuned towards wining and
therefore more sensitive to risk avoidance (Ludvig and Spetch,
2011). Subjects performed the paradigm in two sessions with a
one-minute break in-between. Each of the two sessions lasted for
11 min and included different randomizations of 28 choices between
one and six cards, 28 choices between two and ﬁve cards, 28 choices
between three and four cards and 28 null events of the same length as
a real event where a ﬁxation cross was presented instead of the task
screen. The highest ﬁnal amount of the two sessions was paid to the
participants (average 203 ± 54 DKK).
Serotonergic challenge
Participants were assigned in a randomized counterbalanced fashion
to scanning under each of four conditions: three different serotonergic
challenges and one session without any pharmacological treatment re-
ferred to as “control session”. The three serotonergic challenges
consisted of (i) acute blockade of 5-HT2A receptors with ketanserin,
(ii) acute tryptophandepletion (ATD) to decrease tryptophan availability
in the brain, and (iii) intravenous administration of the SSRI citalopram
to acutely increase levels of free serotonin in the brain. Sessions were
performed at least one week apart to ensure a proper wash-out, using
an identical fMRI protocol that included three fMRI runs during which
participants engaged in a card gambling task, a NoGo task, and an implic-
it face emotion task. Here we only report the results obtained during the
card gambling task. The order of 5-HT challenges and fMRI runswas fully
counterbalanced across subjects to control for task and scan repetition
effects. The citalopram and ATD interventions addressed the opposing
effects of increased versus decreased serotonin levels in the brain, and
these results have been recently reported in a separate paper
(Macoveanu et al., in press). The main purpose of the present study
was to explore the speciﬁc function of the 5-HT2A receptors by compar-
ing behavior and brain responses while the 5-HT2A receptors were
blocked using ketanserin as opposed to the control session.
In the ketanserin session, ketanserin was administrated intrave-
nously, starting with a 10 mg bolus followed by 6 mg/h maintenance
rate during the entire length of the functional image acquisition
(~17.5 mg ketanserin in total). The interval between the bolus and
initiation of the fMRI paradigm ranged from 4 to 69 min across sub-
jects. We estimated the individual average 5-HT2A receptor occupan-
cy rates across the duration of the paradigm to range from 82% to
100%. The estimation was performed based on 5-HT2A occupancy
data from our previous 18F-altanserin PET study that used ketanserin
infusion and which allowed calculation of the time course of the
ketanserin binding and liberation of radioligand from the 5-HT2A re-
ceptors (Pinborg et al., 2003). We measured the blood pressure
every 10 min during the entire session. None of the subjects devel-
oped hypotension during the intravenous ketanserin challenge.
The ATD protocol, which required 24 h of protein diet and ingestion
of an amino acid mixture lacking tryptophan 5 h prior to the MRI in-
vestigation (Macoveanu et al., in press), differed substantially from
the intravenous infusion protocols used to administer citalopram and
ketanserin. For practical reasons with respect to subjects' compliance,
we decided against the intravenous and oral administration of drug
and placebo across all four separate scanning sessions. We wish to
Total: 150
Bet: 5
5              55
Lost 5
A Timeline of a single trial
1100 ms
3500 ms
500 ms
B Possible choices with associated risk levels and reward values
1
6
2 3
5 4
Reward:  33/44/55       3/4/5           12/16/20           3/4/5                 5/6/7              3/4/5 
Fig. 1. The card gambling task. (A) Temporal structure of a single gambling trial. Each trial was divided into three phases: INFORMATION, DECISION and OUTCOME. Subjects ﬁrst
received INFORMATION about the sum of money they had accumulated and the bet size (3, 4 or 5 DKK), which could be lost. In the DECISION phase, two sets of cards facedown were
presented together with the associated monetary reward. Participants chose the set of cards where they believed the “ace of hearts” would be hidden. In the OUTCOME phase, the
“ace of hearts” was revealed, providing the subjects a feedback whether they chose the right set and won the associated reward or lost the bet. (B) The six possible choices with
associated winning amounts in DKK.
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non-speciﬁc effects related to discomfort or distress during intravenous
drug administration because the experiment comprised two intrave-
nous challenges involving intravenous drug administration during the
entireMRI scan.We reasoned that non-speciﬁc effects related to the in-
travenous ketanserin challenge on behavior and neural activity should
also be evident in the data acquired during the citalopram session,
whereas 5-HT2A receptor-speciﬁc effects should only be present in
the ketanserin session. As a post-hoc analysis we validated the ob-
served changes induced by ketanserin compared to the control session
by comparing ketanserin against the citalopram session.
Note that although the pharmacological procedures were not
equivalent across the experimental sessions, participants were not
given any information about potential effects of the drugs that were
given. While subjects were informed of the possible side effects arising
from study participation, they were not informed about which drug
they would be receiving on a speciﬁc day or about the differences inprobabilities of side effects between the different drug interventions
or the expected effects of the 5-HT manipulations.
Behavioral data analysis
The frequency of risk choices and reaction times were entered into
repeated measures analyses of variance (rmANOVA) models (PASW-
SPSS17 Statistics software, Chicago) with ﬁxed factors of type of in-
tervention (2 levels, ketanserin and control) and “risk level” (3 levels,
odds of 4/7, 5/7 and 6/7) as within subject factors. In order to avoid
including perfectly collinear data, we examined the frequencies of
the 4/7, 5/7 and 6/7 choices only. Each of these lower risk options
was paired to a corresponding higher risk option in a forced-choice
design (Fig. 1B). We further set up a post-hoc analysis to test whether
the individual risk preference in a trial (evaluated as the rate of risk
choices with odds smaller than 50%) was inﬂuenced by the risk
level (all 6 levels) and outcome of the immediately preceding trial
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intervention (control and ketanserin), risk (6 levels), and outcome
(negative and positive). Signiﬁcance threshold was set at p b 0.05
using the Greenhouse–Geisser correction for non-sphericity when
appropriate. Conditional on signiﬁcant F-values, pair-wise post-hoc
t-tests were performed to further explore signiﬁcant main effects
and interactions.
MRI data acquisition
All MRI measurements were performed on a 3 Tesla MR scanner
(Siemens Trio, Erlangen, Germany) using an eight-channel head
array coil. The same MRI protocol was performed during the control,
ketanserin and citalopram sessions. BOLD-sensitive fMRI used a
T2*-weighted gradient echo spiral echo-planar imaging (EPI)
sequence with a repetition time (TR) of 2.5 s, echo time (TE) of
26 ms, and ﬂip angle of 90°. The fMRI measurements were obtained
in two fMRI runs, each run lasting 11 min. A total of 260 brain vol-
umes were acquired in a single fMRI session. Each brain volume
consisted of 41 slices with a slice thickness of 3 mm, between-slice
gap of 25%, and a ﬁeld of view (FOV) of 192 × 192 mm using a
64 × 64 grid. The EPI sequence was optimized for signal recovery of
frontal cortex close to the base of the skull by tilting slice orientation
from a transverse towards a coronal orientation by about 30° and the
use of a preparation gradient pulse (Deichmann et al., 2003). In addi-
tion, high-resolution 3D structural T1-weighted spin echo images
were obtained after the ﬁrst session of BOLD fMRI (TI = 800, TE =
3.93, TR = 1540 ms, ﬂip angle 9°; 256 × 256 FOV; 192 slices). After
the BOLD fMRI measurements, we assessed regional blood perfusion
at rest using Arterial Spin Labeling (ASL). The ASL measurements
were performed to test whether any differences in the regional
BOLD signal between ketanserin and control sessions resulted from
a real difference in regional neural activity induced by 5-HT challenge
rather than a mere difference in baseline blood perfusion levels.
ASL-based perfusion measurements used FAIR Q2TIPS (Luh et al.,
1999) sequences with 3D GRASE (Günther et al., 2005) single-shot
readout with background suppression (TR = 3.4 s, TE = 19.3 ms,
TI = 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200,
2400, 2600, 2800, 3000 ms, 2 averages per TI, Q2TIPS saturation dura-
tion = 150 ms, 26 slices, voxel size = 5.0 × 5.0 × 4.0 mm, FOV =
320 × 160 × 104 mm, vessel suppression with bipolar gradients,
b = 6 s/mm2). The duration of the ASL measurements was 4 min
and the sequence was run right after the fMRI session. Pulse and
respiration were recorded during the entire MRI session.
fMRI data analysis
The preprocessing and statistical analysis of the acquired images
was done using SPM5 (http://www.ﬁl.ion.ucl.ac.uk/spm/software/
spm5). The structural images were segmented and the resulting
parameters were used during the normalization of the functional
images. The functional images were realigned to the ﬁrst image,
normalized and smoothed using a symmetric 8-mm Gaussian kernel.
We implemented two event related 1st level subject models, one
for the decision phase and one for the outcome phase of the gambling
task. The decision phase statistical model included six regressors of
interest, one for each risk level (from the lowest odds 1/7, to the
highest odds 6/7). The different choices are illustrated in Fig. 1B.
The model also included one regressor for outcome and one for the
information phase. We identiﬁed brain regions showing an interac-
tion between risk level and type of challenge by including the six
1st level contrasts of interest in a 2nd level ANOVA model with
three factors: “subject” (20 levels), “type of pharmacological chal-
lenge” (2 levels: ketanserin and control) and “risk level” (6 levels:
1/7 to 6/7).The outcome phase 1st level models included negative and posi-
tive outcome regressors separated by the risk level, one decision
and one information phase regressors. Due to interindividual differ-
ences in risk preference, in order to have enough measurements for
all types of outcome events, the negative and positive outcomes
were grouped: choices with odds of 1/7 and 2/7 were modeled to-
gether as a “high-risk” contrast, choices with odds of 3/7 and 4/7 as
a “medium-risk” contrast and choices with odds of 5/7 and 6/7 as a
“low-risk” contrast. Thus, the 1st level outcome models resulted in
six contrasts of interest used for the group level analysis: three nega-
tive and three positive outcome contrasts depending on the risk level.
In order to identify brain regions where ketanserin had an effect on
either negative or positive outcome related activity depending on
the risk level of the decision causing the outcome, we set up a 2nd
level ANOVA model using the negative outcome 1st level contrasts
and a second analog model with the positive outcome 1st level
contrasts. The ANOVA models included three factors: “subject”
(20 levels), “type of pharmacological challenge” (2 levels: ketanserin
and control) and “risk level” (3 levels: high-, medium-, low-risk).
These models were used to assess the main effects of positive and
negative outcomes and to test for interactions between the riskiness
of choice behavior and pharmacological challenge. We evaluated the
direction of the intervention effect by separately comparing individu-
al risk level contrasts of the two challenges.
Differences in response to positive and negative outcomes, as well
as commonly activated regions (conjunction analysis) were assessed
in a separate 2nd level ANOVA model that included an “outcome”
factor (2 levels: positive and negative), a “risk level” factor (3 levels:
high-, medium-, low-risk) and “type of pharmacological challenge”
factor (2 levels: control and ketanserin).
Because the outcome phase always followed the decision phase and
we wanted to assess regions uniquely involved during the outcome
phase we controlled for the carryover effect of the BOLD response dur-
ing the decision phase onto the outcome phase by exclusively masking
the outcome contrasts with the decision contrast at p b 0.001 un-
corrected. In addition to the contrasts of interest, all 1st level models
also included 40 additional nuisance regressors to correct for physio-
logical noise related to pulse (10), respiration (6) and movement
(24) (Glover et al., 2000; Lund et al., 2006).
We were also interested in assessing interaction effects between
ketanserin-induced changes in behavior and brain response. For this
purpose we set up a 2nd level linear regression model that included
the negative outcome low-risk contrasts from the control and
ketanserin groups together with the frequency of low-risk choices
as covariates. The low-risk contrast images were kept separate for
5/7 and 6/7 odds. However, as a few subjects lacked the 6/7 low-
risk negative outcome event we controlled for a possible bias in sub-
ject contributions to the data by verifying the results in a separate
model where the 5/7 and 6/7 low-risk events were pooled together.
The signiﬁcance of the linear relationship between BOLD response
and choice behavior was assessed individually for the control and
ketanserin sessions using linear regression models implemented in
SPM.
To control for possible non-speciﬁc effects of the drug's administra-
tion protocol and indirect effects of drug we rerun all 2nd level models
with the control session substituted by the citalopram session.
We considered clusters to be signiﬁcant at p = 0.05 after Family-
Wise Error (FWE) correction for multiple non-independent compari-
sons applying a cluster-extent threshold of p b 0.005. We also present
exploratory results for contrasts of interest at a reduced voxel-wise
threshold, uncorrected p b 0.001. We report small volume correc-
tions (SVC) for brain regions for which we had a priori hypothesis
(see Introduction). For this end we deﬁned spherical regions of inter-
est (ROIs) with a diameter of 8 mm around lFPC peaks (MNI x,y,
z = −34, 56, −8 and 36, 54, 0) from Boorman et al. (2009) and VS
peaks (MNI x,y,z = −8, 14, −4 and 6, 14, −8) from McCabe et al.
Table 1
Signiﬁcant cluster peaks from the main effect of negative outcomes (vs. baseline),
positive N negative outcomes (see also Fig. 5A) and decision phase analyses across all
risk levels. Voxels are thresholded at p b 0.05 FWE corrected (cluster minimum 10
voxels, sub-peaks separated by N20 mm). Coordinate x,y,z values in MNI standard
stereotactic space, and Z statistics.
Region Side x y z Z-stat
Negative outcomes
Frontopolar cortex Left −40 52 −4 6.7
Right 42 48 −2 N8
Lateral orbitofrontal cortex Left −44 26 −8 N8
Right 47 26 −8 7.8
Anterior insula Left −30 16 −14 N8
39J. Macoveanu et al. / NeuroImage 83 (2013) 35–44(2010). The signiﬁcant clusters are reported with Z-score and stereo-
tactic MNI coordinates of the regional maxima.
Mood assessment
Participants completed a modiﬁed Danish version of the Proﬁle of
Mood States (POMS) questionnaire (McNair et al., 1971) to assess
current mood according to six domains: tension/anxiety, depres-
sion/dejection, anger/hostility, vigor/activity, fatigue/inertia and con-
fusion/bewilderment. For both the control and ketanserin sessions,
participants completed the mood questionnaire twice at each session:
upon arrival and immediately after the fMRI scan.
Cerebral blood perfusion analysis
The ASL-based brain perfusion measurements were analyzed
using FABBER with spatial priors (http://www.fmrib.ox.ac.uk/fsl/
fabber). Perfusion differences between control and ketanserin ses-
sions were evaluated using permutation-based statistics. We made
two perfusion contrasts at an extended threshold of p b 0.01
uncorrected for multiple comparisons for increased and decreased
perfusion levels between the control and ketanserin sessions. The
two contrasts were tested as exclusive masks for the BOLD contrasts
in order to exclude regions showing perfusion changes from contrasts
with BOLD changes induced by ketanserin.
Results
Behavioral results
As intended, participants distributed the selection of choices rela-
tively evenly across the six risk levels (Fig. 2). Acute blockade of the
5-HT2A receptor resulted in a shift towards more risk-averse choices.
Participants made signiﬁcantly more low-risk choices during the
ketanserin session compared to the control session (F1,19 = 5.3,
p b 0.05). An additional ANOVA addressing the dependence of risk
preference on the risk level and outcome of the immediately preced-
ing trial again showed a main effect of drug intervention with less
high-risk choices in the ketanserin session (F1,19 = 4.60, p b 0.05)
and a main effect of risk level (F3,62 = 4.6, p b 0.01). There was
also an interaction between risk level and the outcome (negative or
positive) of the preceding trial (F4,75 = 8.1, p b 0.001): both, losing
a low-risk bet or winning a high-risk bet, facilitated risk averse deci-
sions in the next trial. Conversely, winning a low-risk bet and losing a
high-risk bet prompted subjects to make more often risky decision in
the next trial. This recency effect on risk-taking was not modulated by
ketanserin.
Reaction times were not inﬂuenced signiﬁcantly by the ketanserin
challenge. There was however signiﬁcant inﬂuence of risk level on10%
15%
20%
25%
1/72/73/74/75/7 6/7
Risk level
Control
Ketanserin
Low risk High risk
Mean ± SEM, N=20
Fig. 2. Distribution of risk choices across the six different risk levels. Ketanserin led to a
signiﬁcant increase in the frequency of low-risk choices.reaction times (F(3,58) = 5.1, p b 0.01). A post-hoc analysis revealed
a signiﬁcant quadratic effect of risk level. Decisions between similar
risk choices (3/7 and 4/7) were associated with the longest reaction
times, presumably due to a higher ambiguity of this choice condition.
This inverse U-shaped effect was signiﬁcant only for the control
session (F(2,12) = 3.2, p b 0.05).Neural response to negative outcomes
Negative outcomes (i.e. losing a bet) independent of risk level and
drug intervention consistently increased neural activity as indexed by
the BOLD response in a bi-hemispherical network encompassing the
medial frontal cortex, lateral orbitofrontal cortex (OFC), anterior insu-
lar cortex, lateral prefrontal and frontopolar cortex (Table 1). The
group-by-risk ANOVA analysis yielded a signiﬁcant interaction be-
tween the risk level (low vs. high) and the effect of ketanserin on the
BOLD response to negative outcomes in the right lFPC ([42 56 −2],
Z = 3.3, psvc = 0.04) and right VS [10 14 −14], Z = 3.3, psvc =
0.05), indicating a differential effect of ketanserin on processing nega-
tive outcomes depending on the risk level. Post-hoc tests
revealed that 5-HT2A receptor blockade by ketanserin attenuated the
BOLD response to low-risk negative outcomes in lFPC bilaterally and
ventral regions of the right OFC (Fig. 3, Table 2). Noteworthy, this effect
was found signiﬁcant only for negative outcomes caused by low-risk
decisions that resulted in a high missed reward, and not for negative
outcomes caused by medium-risk and high-risk decisions. The interac-
tion in right VS was driven by both a non-signiﬁcant attenuation of the
response to low-risk negative outcomes and a non-signiﬁcant increase
of the response to high-risk negative outcomes during the ketanserin
session.
The 2nd level linear regression model testing the individual choice
preference (indexed by the frequency of low-risk choices with odds
of 5/7 and 6/7) as a function of BOLD response to negative outcomes
revealed a signiﬁcant group-by-behavior interaction in VS (Fig. 4). In
a state of normal 5-HT2A receptor function (control condition), the VSRight 34 14 12 N8
Inferior parietal cortex Left −58 −50 36 N8
Right 56 −48 42 N8
Middle frontal gyrus Left −38 10 50 6.8
Right 42 10 46 N8
Caudate Left −8 0 4 6.7
Right 10 0 6 N8
Medial frontal cortex Both −2 44 34 N8
Positive outcomes N negative outcomes
Ventral striatum Left −16 4 −12 7.3
Right 16 6 −14 7.6
Precuneus Left −20 −66 32 5.9
Right 12 −56 22 5.5
Posterior cingulate cortex Both −4 −38 38 5.7
Decision phase (increased response with high risk)
Ventral striatum Left −10 10 −8 5.3
Right 16 4 −12 5.0
Inferior parietal lobe Left −38 −42 56 4.9
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C
Fig. 3. Bilateral reductions in the neural response to negative outcomes caused by low-risk decisions in lateral frontopolar cortex after 5-HT2A blockade. Choices with odds of 1/7 and
2/7 were pooled together as high-risk, choices with odds of 3/7 and 4/7 as medium-risk and choices with odds of 5/7 and 6/7 as low-risk. The ﬁgure shows the control N ketanserin
contrast for low-risk choices. Left panels, for low-risk negative outcomes, ketanserin decreased right and left lateral frontopolar cortex activity compared to the control condition.
The maps are thresholded at p b 0.01 (uncorrected) for illustrative purposes. The right panels give the parameter estimates of the regional peaks for the negative outcomes caused
by low, medium and high-risk choices and serotonergic challenge. Error bars represent 90% conﬁdence interval of the mean.
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those subjects who relatively frequently chose high-risk options
(i.e., bets with an odds of 1/7 or 2/7). Conversely, subjects who
made more low-risk choices showed a weaker VS response when
these low-risk choices turned out to be unsuccessful (Fig. 4, right
panel). The ketanserin induced change in the slope of the linear rela-
tionship between the BOLD response to negative outcomes and riskTable 2
Peak differences between low-risk negative outcome contrasts from the Control vs. Ketanse
sub-peaks separated by N20 mm). Coordinate x,y,z values in MNI standard stereotactic spa
Control N Ketanserin
Region Side x y z
Frontopolar cortex Left −36 48 4
Right 44 54 −2
Orbitofrontal cortex Right 20 28 −18
Correlation with risk preference Ketanserin N Control
Ventral striatum Left −14 6 −12
Right 16 8 −14
Superior frontal sulcus Right 18 8 46preference was signiﬁcant in both right and left VS and right superior
frontal sulcus (Table 2). Because some of the subjects lacked either
the 5/7 or 6/7 low-risk negative outcome event, the analysis was re-
peated with pooled 5/7 and 6/7 events. The additional analysis was
consistent with the initial one showing a trend interaction between
the effect of ketanserin and frequency of low-risk choices in right
VS ([8 14 −16], Z = 3.0, p = 0.001).rin and Citalopram vs. Ketanserin analyses (clusters surviving p b 0.05 FWE correction,
ce, and Z statistics.
Citalopram N Ketanserin
Z-stat x y z Z-stat
4.0 −36 52 2 3.8
4.5 44 54 −2 3.4
4.5 14 26 −18 3.8
Ketanserin N Citalopram
3.9 n/a
4.2 16 10 −16 3.5
4.0 n/a
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Fig. 4. Change in the correlation between the regional response to low-risk negative outcomes and risk-averse behavior after 5-HT2A blockade. The left panels display regions show-
ing differential correlations (control N ketanserin) between the response to low-risk negative outcomes and mean normalized frequency of low risk choices (5/7 and 6/7), maps
thresholded at p b 0.01 (uncorrected) for illustrative purposes. Right panel shows the plot of the linear regressions for the control and ketanserin groups in the regional peak of
ventral striatum.
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sponse to negative outcomes (control session) and relative frequency
of low-risk choices (5/7 and 6/7) yielded a negative correlation in
right VS ([18 12 −2], Z = 3.4, p b 0.001 uncorrected) and left VS
([−14 0 −10], Z = 3.9, p b 0.001 uncorrected). The analog analysis
for the ketanserin session did not yield a signiﬁcant correlation in VS.
Neural response to positive outcomes
Positive outcomes (i.e. winning a bet) activated a partially
overlapping network of brain regions as for negative outcomes. Yet,
when contrasting the BOLD response to positive and negative out-
comes, several clusters displayed a signiﬁcantly stronger response
to positive relative to negative outcome activity independently of
risk level or drug intervention (Table 1). Notably, the largest clusters
showing a stronger activation for positive outcomes were found in VS
(Fig. 5A). There were no signiﬁcant clusters showing higher response
to negative outcomes compared to positive outcomes. The group-
by-risk ANOVA analysis yielded no signiﬁcant interaction between
the risk level and effect of ketanserin. However, paired tests revealed
a cluster in right lateral OFC showing a trend towards an attenuated
BOLD response to high positive outcomes caused by high-risk choices
when 5-HT2A receptors had been acutely blocked (peak in right OFC
at [12 22−20], Z = 3.5, p b 0.001 uncorrected). A conjunction anal-
ysis revealed that this cluster overlapped with the region showing a
reduced BOLD response to low-risk negative outcomes under
5-HT2A receptor blockade (Fig. 5B). Critically, no effects of 5-HT2A
receptor blockade could be observed in relation to positive outcomes
in the lateral frontopolar region and VS even when applying a liberal
statistical threshold (p b 0.01, uncorrected).
Neural activity during the decision phase
During the decision phase, we found a signiﬁcant effect of risk
magnitude of the choice with a positive linear increase in VS and
left inferior parietal lobe response with the risk level (Table 1).
There was, however, no signiﬁcant interaction between the risk
level and the ketanserin intervention during the decision phase.Mood assessment
The participants completed a Proﬁle of Mood States (POMS) form
upon arrival at every investigation day as well as right after the fMRI
session. The POMS scores allowed us to identify mood changes caused
by the scanning session itself as well as changes related to the admin-
istration of ketanserin. An ANOVA analyses including the factors 5-HT
challenge (ketanserin vs. no drug condition) and time of measurement
(before vs. after the fMRI run), yielded neither a main effect of 5-HT2A
receptor blockade nor a challenge × time interaction for any of the
reported mood states. We did however ﬁnd a non-speciﬁc time effect
with decreased anger (F(19) = 12.2, p = 0.002) and vigor (F(15) =
9.2, p = 0.009) scores and increased fatigue scores (F(15) = 7.6,
p = 0.014) at the end of the scanning session compared to upon
arrival scores which was unrelated to the pharmacological challenge.
Considering the ketanserin session alone, we found an expected
decrease in vigor/activity (t(18) = 4.0, p = 0.001), and increase in
fatigue/inertia (t(18) = −3.4; p = 0.004) when contrasting upon
arrival scores with end of session scores. In order to control whether
ketanserin's observed effect on risk behavior and BOLD response
might have been driven by changes in vigor/activity or fatigue/inertia,
we included these POMS values as covariates in the statistical models
for behavior and BOLD responses. Critically, the changes in vigor/activity,
fatigue/inertia following ketanserin administration did not predict either
the increased risk aversion or the altered BOLD response to low-risk
negative outcomes reported above.
Perfusion analysis
We found increased baseline level blood perfusion following
ketanserin administration in a widespread prefrontal area including
anterior cingulate cortex and inferior frontal regions with right side
prevalence (at the signiﬁcance level accepted for the fMRI analysis).
Exclusive masking of our fMRI contrasts with Arterial Spin Labeling
(ASL) images revealed that none of the regions showing increased
perfusion overlapped with lateral fronto-cortical regions found to be
attenuated by ketanserin during negative outcomes or the ventral
striatal regions that correlated with the change in risk-taking behav-
ior. We did not ﬁnd any signiﬁcant decrease in perfusion levels for the
t-score
2          3          4          5          7          8
A
R
Y=6
X=12
A
B
Fig. 5. A) Regions where positive outcomes elicited higher BOLD response than negative
outcomes (p b 0.05 FWE corrected) across all risk levels. B) Conjunction analyses show-
ing reduced activity in orbitofrontal cortex during both low-risk negative outcomes and
high-risk positive outcomes in the ketanserin session relative to the control session
(shown at p b 0.01 uncorrected for illustrative purposes).
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perfusion levels in ventrolateral prefrontal cortex and VS we conclude
that in these regions the observed attenuation in BOLD response
following ketanserin infusion are likely to reﬂect altered neural activity.Comparison between the ketanserin and citalopram sessions
There was no signiﬁcant difference in risk choice behavior be-
tween the citalopram and control sessions. Critically, we were able
to replicate the ketanserin induced risk aversion when comparing
the ketanserin with citalopram sessions (F1,19 = 10.0, p = 0.005).
Substituting the functional images from the control session with the
images from the citalopram session revealed similar results, with
ketanserin decreasing BOLD response bilaterally in lFPC for low-risk
negative outcomes and inverting the linear relationship betweennegative outcome related striatal activity and risk preference (see
Table 2).
Discussion
Our present data provide direct evidence for a causal link between
risk avoidance and 5-HT2A receptor related serotonergic neurotrans-
mission. The increased tendency to “play-it-safe” after 5-HT2A receptor
blockade indicates that normal 5-HT2A receptor function tunes behav-
ior towards more risk-taking behavior. Concurrent fMRI measurements
revealed that 5-HT2A receptors contribute to the processing of negative
outcomes in lFPC caused by low-risk decisions. Further, normal 5-HT2A
receptor function is associatedwith a stronger responsiveness of the VS
to low-risk negative outcomes the more risk-seeking the individual be-
havior is. This relationship was inverted by 5-HT2A receptor blockade.
The observed effects were speciﬁc to 5-HT2A receptor blockade because
they are not observed in general pharmacological manipulations of
5-HT levels (Macoveanu et al., in press).
Increased risk aversion after 5-HT2A receptor blockade
The increased propensity for low-risk choices under ketanserin
suggests that 5-HT2A receptor-related neurotransmission is involved
in regulating risk aversion, favoring risky choices, possibly via its
facilitatory effects on dopaminergic mesolimbic and nigrostriatal
projections (Alex and Pehek, 2007; Boureau and Dayan, 2011). While
the propensity to choose the less risky options was inﬂuenced by the
outcome of the preceding trial in relation to the risk level (either losing
a low-risk bet or winning a high-risk bet prompted more risk averse
behavior in the following trial), this recency effect was not modulated
by ketanserin. Our results suggest that ketanserin exerted a more
sustained effect on risk avoidance rather than altering risk choice
behavior according to the recent outcome history.
Within the framework of the prospect theory (Kahneman and
Tversky, 1979), the 5-HT2A receptor blockade weakened the relative
decision weight of low probabilities with high potential reward or
strengthened the decision weights of high probabilities with low
potential reward, or both. Noteworthy, the potential losses were
relatively small as opposed to wins and kept constant across trials.
This introduced a “gain frame” that tuned decision making towards
“risk aversion for gains” rather than “risk seeking for losses” (Ludvig
and Spetch, 2011).
The increased risk aversion after acute 5-HT2A receptor blockade
contrasts with the observed effects of global serotonergic challenges.
In the same group of subjects, neither dietary ATD nor SSRI interven-
tion affected risk-taking behavior (Macoveanu et al., in press).
Interestingly, in that study, the two serotonergic challenges affected
different parts of the reward system, namely amygdala and
dorsomedial PFC. Global manipulation of 5-HT availability might
have a variable impact on a broad range of 5-HT receptors that
might have opposing effects on risk-taking and risk-aversion. This
could explain the dissimilar effects observed for ketanserin and
ATD. Other studies on healthy volunteers have reported conﬂicting
results. ATD was found to either stimulate (Long et al., 2009; Rogers
et al., 1999a, 1999b) or not impact risk-taking behavior (Cools et al.,
2008; Rogers et al., 2003).
Reduced response of lateral frontopolar and orbitofrontal cortex after
5-HT2A receptor blockade
At baseline, a region in left and right lFPC responded to negative
outcomes caused by low-risk choices (Fig. 3, right panels). In these
instances, a play-it-safe strategy did not pay off as participants missed
out on a large reward. These regions did not process negative out-
comes following high-risk choices when the missed reward was min-
imal. Because the size of losses was kept constant across risk choices,
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design did not allow to directly differentiate whether the lFPC reacts
preferentially to the magnitude of missed reward or to low-risk
negative outcomes, previous neuroimaging work might provide
possible clues: while the lFPC has not been found to scale with losses,
it has been shown that this region tracks the missed rewards of the
best unselected choice and maintains this information across time
in favor of their future employment (Boorman et al., 2009, 2011).
Interestingly, patients with orbitofrontal lesions are no longer able
to account for the reward of an alternative choice (Camille et al.,
2004). We therefore argue that the lFPC processed the magnitude of
the missed reward of the alternative unselected choice, when sub-
jects “played-it-safe” but still lost. The magnitude of missed rewards
for low-risk options is much higher than the magnitude of missed
rewards following high-risk options. This difference in the missed
reward may account for the selective behavioral effect of ketanserin
on low-risk choices. We suggest that the lFPC generates a 5-HT2A
receptor-dependent outcome signal leading to an overall reinforce-
ment of risk-taking behavior. When 5-HT2A receptor signaling is
blocked by ketanserin, this reinforcement signal is destabilized, ren-
dering subjects less responsive to high missed rewards, thus tuning
the “decision weights” of win probabilities.
OFC is a critical component of the reward network being involved in
the evaluation of both rewarding and aversive stimuli (Liu et al., 2007;
O'Doherty, 2004). Recent studies have demonstrated that OFC activity
is modulated by 5-HT. For instance, increasing 5-HT availability by
SSRI treatment of healthy volunteers found decreased neural response
to aversive gustatory stimuli in OFC (McCabe et al., 2010). We show
that blocking the 5-HT2A receptors leads to an attenuation of the OFC
response, but compared to the frontopolar region, the region in OFC
responded less to both low-risk negative outcomes and high-risk
positive outcomes. We therefore suggest that 5-HT2A related signaling
enhances the responsiveness of OFC to “surprising” events, including
unlikely positive outcomes with high rewards as well as unlikely
negative outcomes with high missed rewards (Schoenbaum et al.,
2009).
Altered relationship between choice behavior and negative outcome
processing in ventral striatum
In an fMRI study on the neural correlates of loss aversion, Tom et
al. (2007) found that inter-individual differences in behavioral loss
aversion predicted inter-individual differences in VS activity coding
“decision utility”. The group further showed a negative correlation
between the magnitude of potential losses and VS response. Since
people prefer avoiding losses to making gains, we suggest that
while evaluating possible gains in our task, behavioral loss aversion
is linked to behavioral risk aversion. The present results therefore
provide new evidence that the evaluation of missed reward caused
by low-risk choices in VS also correlates (negatively) with individual
risk-averse behavior: in the context of normal 5-HT2A receptor func-
tion, large missed rewards caused by low-risk decisions induced
weaker VS response in subjects that were relatively more risk averse.
Noteworthy, this pattern was not observed in frontopolar areas. We
suggest that in normal condition, VS evaluates salient negative out-
comes (low-risk) assigning higher value to these events the less fre-
quently they occur (Zink et al., 2004). Because risk-seeking subjects
choose low-risk options less frequently, they would show a higher
VS response to negative outcomes following low-risk choices com-
pared to risk avoiding individuals. The VS response to these salient
events may therefore reinforce risk-seeking behavior. Blockade of
the 5-HT2A receptors may reduce the saliency of these events either
by means of neuromodulatory action or indirectly, as consequence
of the overall increased risk aversiveness.
Previous studies have provided evidence that 5-HT modulates the
VS response to primary reward stimuli. For instance, following aseven-day SSRI intervention, Abler et al. (2012) showed reduced VS
response to erotic visual stimuli and McCabe et al. (2010) show
reduced VS response to pleasant taste. Compared to primary rewarding
stimuli like sexual and gustatory stimuli, monetary gains are secondary
reinforcers. This might explain why ketanserin did not have a consis-
tent direct effect on VS response to monetary outcomes in the present
study. Even though limbic reward areas including VS and OFC have
been found to process both primary and secondary reinforcers, there
is also evidence that reward-related regions might be stimulus speciﬁc
(Lamy, 2007). Our data support the view that 5-HT modulation of VS
might be limited to primary reward stimuli.
Methodological considerations
While ketanserin has the highest afﬁnity for the 5-HT2A receptors, it
also binds to histamine H1 receptors, and has low afﬁnity binding for
5-HT2C and alpha-1 adrenergic receptors (Glennon et al., 2002;
Korstanje et al., 1986). These low afﬁnity interactionswith other neuro-
transmitter systems might have contributed to the observed effects, in
addition to an indirect inﬂuence of 5-HT2A receptors on dopaminergic
neurons (Pehek et al., 2001).
We checked for possible non-speciﬁc effects of intravenous
ketanserin administration by rerunning the analyses comparing the
ketanserin with citalopram session in the same subjects. The behavior
and neuroimaging effects of ketanserin that were found in comparison
with the control session were fully replicated in a direct comparison
against the citalopram challenge. Additional post-hoc analyses veriﬁed
that ketanserin's effect on mood states and cerebral blood perfusion
did not account for the ketanserin-induced task speciﬁc changes in
BOLD response.
Conclusion
In conclusion, we suggest that 5-HT2A receptors are involved in the
generation of negative outcome signals caused by risk-averse choices,
which led to high missed rewards, thereby reinforcing risk-taking be-
havior. Our ﬁndings are of relevance for understanding the role of
5-HT2A receptor signaling in psychiatric disorders. For instance, the
5-HT2A receptors have been linked to personality traits like neuroticism
(Frokjaer et al., 2008) and impulsivity (Nomura et al., 2006) and exces-
sive concentration of 5-HT2A receptors in prefrontal cortex has been
reported in individuals with major depression (Shelton et al., 2009).
Drugs designed to selectively target the 5-HT2A system may therefore
beneﬁt patients with speciﬁc types of neuropsychiatric disorders. The
present results underscore the potential of receptor speciﬁc pharmaco-
logical manipulations, being able to tap into the distinct function of the
different 5-HT receptors. As such, receptor-speciﬁc pharmacological
challenges complement more general pharmacological manipulations
of 5-HT neurotransmission in humans such as dietary tryptophan de-
pletion. Pharmacological fMRI can be used to map the impact of these
speciﬁc challenges on speciﬁc neural networks and hereby, can provide
valuable insights into the role of the serotonergic system in reward
processing and decision-making.
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